NCT03157128 · OUTCOME

Phase 2: Best Change in Tumor Size From Baseline (by IRC and Investigator)

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) · Source last updated 2026-04-16

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Approximately for up to 9 years 8 months

What was measured

Phase 2: Best Change in Tumor Size from Baseline (by IRC and Investigator)

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

anticipated Posting Date: 2028-02
denom Units Selected: Participants
description: Phase 2: Best Change in Tumor Size from Baseline (by IRC and Investigator)
reporting Status: NOT_POSTED
time Frame: Approximately for up to 9 years 8 months
title: Phase 2: Best Change in Tumor Size From Baseline (by IRC and Investigator)
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice